Teva and Prestige Biopharma enter license agreement for Tuznue commercialization in Europe
Tuznue is a biosimilar of Herceptin (trastuzumab), developed to offer a more cost-effective therapeutic alternative for patients
3 Nov 2025
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. has entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets.
Tuznue® is approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received the European Commission (EC) marketing authorization for Tuznue® in September 2024.
Under the terms of the license and supply agreement, Teva has secured the rights to market and distribute Tuznue® in a majority of European markets, leveraging its extensive commercial network and proven expertise in biosimilars. Prestige Biopharma will be responsible for production and supply through its EU-GMP-certified, high-tech facilities equipped with advanced single-use technology.
Richard Daniell, Executive Vice President, European Commercial, Teva, said, “Our deep commercial experience in biosimilars and broad sales and marketing reach across Europe enables us to bring critical medicines to patients. We are looking forward to working together with Prestige to make Tuznue® a commercial success in Europe.”
Lisa Park, CEO of Prestige Biopharma, said, "This collaboration is a significant step in establishing Prestige Biopharma as a global biopharmaceutical leader. Teva’s extensive market reach will drive the successful launch of Tuznue® while accelerating the development of our broader biosimilar pipeline, including bevacizumab and 14 additional candidates."